Last 42 quarters of trend data · Healthcare · Diagnostics & Lab Testing
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.58 | 8.93 | 6.35 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -49.4% | +76.7% | -0.9% | |
| P/S Ratio | 0.40 | 20.11 | 7.18 | 6.39 | 22.41 | 14.23 | 49.40 | 41.50 | 14.86 | 3.54 | 33.06 | 2.92 | 3.17 | 40.81 | 18.12 | 13.88 | 4.93 | 9.07 | 2.36 | 3.28 | 2.42 |
| — | +41.3% | -85.5% | -84.6% | +50.8% | +301.5% | +49.4% | +1319.6% | +369.4% | -91.3% | +82.4% | -78.9% | -35.8% | +350.1% | +667.0% | +323.4% | +103.8% | +304.4% | -33.9% | +36.3% | -47.5% | |
| P/B Ratio | 0.02 | 1.05 | 0.26 | 0.33 | 0.33 | 0.23 | 0.21 | 0.46 | 0.60 | 0.52 | 0.43 | 0.48 | 0.31 | 0.31 | 0.39 | 0.68 | 0.75 | 1.26 | 1.45 | 1.99 | 2.91 |
| — | +366.4% | +26.0% | -28.4% | -45.2% | -56.7% | -51.4% | -5.6% | +91.0% | +66.6% | +8.2% | -28.8% | -58.0% | -75.2% | -72.8% | -65.8% | -74.4% | -55.2% | -61.3% | -49.2% | -61.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 28.30 | 39.71 | 7.24 | 14.06 | 6.42 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +340.5% | +688.6% | +22.7% | +319.6% | -46.0% | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.92 | 4.30 | 3.80 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -46.8% | +26.7% | -51.8% | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.99 | 4.34 | 3.83 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -48.2% | +25.7% | -51.6% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.3% | 72.7% | -207.8% | 46.0% | 81.9% | 80.3% | 57.1% | -70.8% | 53.6% | 92.0% | 7.2% | 16.5% | 89.6% | -132.1% | 16.6% | 63.2% | 84.9% | 81.8% | 85.5% | 87.8% | 89.0% |
| — | -9.4% | -464.2% | +165.0% | +52.8% | -12.7% | +690.6% | -528.6% | -40.2% | +169.7% | -56.4% | -73.9% | +5.5% | -261.5% | -80.6% | -28.0% | -4.6% | -10.0% | +2.3% | +4.4% | +21.4% | |
| Operating Margin | -5025.5% | -3732.5% | -6309.1% | -2902.3% | -4824.5% | -4946.1% | -17009.7% | -7973.9% | -1596.4% | -289.1% | -4059.2% | -332.6% | -363.7% | -6063.7% | -1653.0% | -1863.8% | -128.3% | -82.6% | 43.3% | 50.5% | 45.3% |
| — | +24.5% | +62.9% | +63.6% | -202.2% | -1611.1% | -319.0% | -2297.3% | -338.9% | +95.2% | -145.6% | +82.2% | -183.5% | -7244.9% | -3919.4% | -3788.6% | -383.3% | -291.6% | -16.1% | -14.4% | -17.9% | |
| Net Margin | -7533.6% | -3782.4% | -6262.3% | -9755.1% | -4049.3% | -4745.0% | -14983.5% | -7387.4% | -1512.4% | -286.0% | -3684.4% | -412.8% | -243.5% | -4508.9% | -956.1% | -1563.0% | -26.7% | -53.5% | 51.6% | 36.8% | 38.1% |
| — | +20.3% | +58.2% | -32.1% | -167.7% | -1558.9% | -306.7% | -1689.5% | -521.2% | +93.7% | -285.3% | +73.6% | -811.3% | -8331.3% | -1952.6% | -4352.6% | -170.1% | -249.5% | +30.8% | -22.1% | -47.1% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -125.2% | -43.7% | -49.8% | -85.2% | -14.5% | -17.4% | -14.7% | -18.7% | -14.2% | -10.1% | -11.3% | -15.8% | -5.9% | -8.3% | -5.1% | -17.6% | -1.0% | -1.8% | 8.3% | 6.4% | 12.2% |
| — | -151.8% | -238.2% | -355.9% | -2.1% | -72.2% | -30.1% | -18.1% | -141.5% | -21.0% | -121.6% | +9.9% | -505.2% | -353.2% | -161.6% | -374.8% | -108.0% | -115.4% | -24.9% | -70.2% | -66.5% | |
| ROA | -105.7% | -33.0% | -39.5% | -74.1% | -12.9% | -15.2% | -12.6% | -16.2% | -12.7% | -9.1% | -10.2% | -14.4% | -5.4% | -7.8% | -4.8% | -16.2% | -0.9% | -1.6% | 7.1% | 5.6% | 11.6% |
| — | -116.9% | -212.6% | -358.1% | -1.9% | -67.5% | -23.6% | -12.4% | -134.5% | -17.0% | -113.4% | +11.0% | -512.5% | -379.7% | -167.9% | -386.8% | -107.6% | -114.4% | -31.9% | -72.3% | -66.5% | |
| ROIC | -73.9% | -44.9% | -69.7% | -28.8% | -17.1% | -15.2% | -12.6% | -16.4% | -13.2% | -9.7% | -11.6% | -10.7% | -7.2% | -9.1% | -7.6% | -26.9% | -8.7% | -5.7% | 15.2% | 24.4% | 59.3% |
| — | -196.1% | -451.2% | -75.8% | -29.6% | -56.9% | -8.5% | -53.9% | -82.0% | -6.4% | -53.8% | +60.3% | +16.7% | -60.3% | -149.7% | -210.2% | -114.7% | -111.4% | -58.5% | -43.9% | +52.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.14 | 0.13 | 0.06 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| — | +241.7% | +214.1% | +51.3% | -0.5% | +16.1% | +13.1% | +14.0% | +21.3% | +14.2% | +321.3% | +1044.5% | +886.0% | +822.4% | +123.4% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.06 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.87 | 1.81 | 2.28 | 3.87 | 3.81 | 4.12 | 4.43 | 4.41 | 6.92 | 9.09 | 10.19 | 10.81 | 13.99 | 15.13 | 23.80 | 23.94 | 16.95 | 17.06 | 9.63 | 9.14 | 24.83 |
| — | -56.0% | -48.5% | -12.4% | -45.0% | -54.6% | -56.5% | -59.2% | -50.6% | -39.9% | -57.2% | -54.8% | -17.5% | -11.3% | +147.3% | +162.0% | -31.7% | -10.7% | -47.6% | -45.7% | -13.3% | |
| Quick Ratio | 3.59 | 1.52 | 2.09 | 3.59 | 3.51 | 3.83 | 4.23 | 4.27 | 6.70 | 8.81 | 9.90 | 10.52 | 13.10 | 14.21 | 22.33 | 22.57 | 16.05 | 16.36 | 9.25 | 8.98 | 24.03 |
| — | -60.4% | -50.7% | -15.9% | -47.6% | -56.5% | -57.2% | -59.4% | -48.9% | -38.0% | -55.7% | -53.4% | -18.3% | -13.1% | +141.5% | +151.4% | -33.2% | -10.3% | -45.4% | -39.6% | +5.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 42 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CODX stock.
Co-Diagnostics, Inc.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Co-Diagnostics, Inc.'s current operating margin is -5025.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Co-Diagnostics, Inc.'s business trajectory between earnings reports.